References

References

01/01
1 of 1
Ref. 1
Benavente-García García, O. & Castillo Sánchez, J. Food composition for functional foods and nutritional supplements. (2009).
Ref. 2
Katsenis, K. Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency. Current Vascular Pharmacology 3, 1-9 (2005).
Ref. 3
Roztočil, K., Štvrtinová, V. & Strejček, J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int. Angiol. 22, 24–31 (2003).
Ref. 4
Struckmann, J. R. & Nicolaides, A. N. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology 45, (1994).
Ref. 5
MacKay, D. Hemorrhoids and varicose veins: a review of treatment options. Altern. Med. Rev. 6, 126–140 (2001).
Ref. 6
Godeberge, P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 45, 574–8 (1994).
Ref. 7
Ho, Y.-H., Foo, C. L., Seow-Choen, F. & Goh, H. S. Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy. Br. J. Surg. 82, 10341035 (1995).
The regulations governing food, food additives, dietary supplements and cosmetics do vary between countries, and the use of some products may be restricted in some places. Therefore, customers are requested to observe the appropriate regulations when using these products. While the information provided in this document is presented in good faith and believed to be accurate, it does not bind Ferrer HealthTech under any legal obligations. It is presented only for your guidance. Any information in this document may change without prior notice.